Mattsson N, et al. - Via a cohort study of 1,583 people in the multicenter Alzheimer’s Disease (AD) Neuroimaging Initiative study from September 7, 2005 through June 16, 2016, researchers investigated whether longitudinal plasma neurofilament light (NfL) levels were correlated with other hallmarks of AD, since NfL has been suggested as a noninvasive biomarker to monitor neurodegeneration in AD. In subjects with mild cognitive impairment and AD dementia, the NfL level was higher at baseline and increased in all diagnostic groups, with the largest rise in patients with AD dementia. A quicker increase in NfL levels corresponded with a quicker rise in CSF biomarkers of neuronal injury, quicker rates of atrophy and hypometabolism, and quicker deterioration in global cognition. In patients with AD, plasma NfL could be a noninvasive biomarker correlated with neurodegeneration and could helpmonitor impacts in trials of disease-modifying drugs.